Inhibition effects of methylprednisolone on over-expression of transforming growth factor-β1 (TGF-β1) in kidneys of BXSB mice

Abstract

Abstract: AIM: To investigate the relationship between TGF-β₁ over-expression and lupus nephritis(LN) in BXSB mice and whetherMPS ameliorates LN by inhibiting the over-expression of TGF-β₁. METHODS: BXSB mice (experiment group, n = 6) were treated (i.p.) with MPS (25 mg·kg^-1·d^-1) dissolved in N. S for 3 weeks. The other age and sex-matched BXSB mice (n =6) and BALB /c mice (n =6) received N. S. alone. Proteinuria production was evaluated once a week. The expression of TGF-β₁ in the kidney was investigated by means of immunohistochemistry and RT-PCR. RESULTS: MPS significantly reduced proteinuria of BXSB mice (P<0.01). TGF-β₁ was strongly expressed in kidneys of all BXSB mice, while weak expressions were found in kidneys of BALB /c mice. A significant lower expression of TGF-β₁ was found in the BXSB experiment group compared with BXSB control group (P <0.01). CONCLUSION: The over-expression of TGF-β₁ may aggravate LN, while MPS partially ameliorates LN by inhibiting the expression of TGF-β₁.

Key words: methylprednisolone, lupus nephritis, kidney, transforming growth factor-β₁, mouse

CLC Number:

R977.1

WANG Mei-mei, ZHU Xiao-xia, SUN Ru-rong, XU Lei-ting. Inhibition effects of methylprednisolone on over-expression of transforming growth factor-β₁ (TGF-β₁) in kidneys of BXSB mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(7): 799-803.

References

1 Ostendorf T, Kunter U, van Roeyon C, Dooley S, Janjic N, Ruckman J, et al.The effect of platelet derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system[J]. J Am Soc Nephrol, 2002; 13:658-67
2 Blom IE, van Dijk AJ, Wieten L, Duran K, Ito Y, Kleij L, et al.In vitro evidence for differential involvement of CTGF, TGF-B, PDGF-BB in mesangial response to injury[J]. Nephrol Dial Transplant, 2001;16: 1139-48
3 Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT, et al.Role of matrix metalloproteinase 1, 2 and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency[J]. J Vasc Surg, 2001;34:930-8
4 Bouletreau PJ, Steinbrech D, Spector JA, Warren SM, Greenwald JA, Mehrara BJ, et al.Gene expression of transforming growth factor-beta 1 and tissue inhibitor of metalloproteinase type 1 during membranous bone healing in rats[J]. J Craniofac Surg, 2000;11:52-6
5 Wogensen L, Nielsen CB, Hjorth P, Rasmussen LM, Nielsen AH, Gross K, et al.Under control of the Ren-1C promoter, locally produced transforming growth factor-β₁ induce accumulation of glomerular extracellular matrix in transgenic mice[J]. Diabetes, 1999;48: 182-92
6 Basile DP. The transforming growth factor-beta sy stem in kidney disease and repair: recent progress and future directions[J]. Curr Opin Nephrol Hypertens, 1999;8:21-30
7 Imai E, Isaka Y, Akagi Y, Kaneda K, Hori M.Gene transfer and kidney disease[J]. J Nephrol, 1998;11: 16-9
8 Leivo T, Arjomaa P, Oivula J, VesterinenM, Kiistala U, Autio P, et al.Differential modulation of transforming growth factorbeta by betamethasone-17-valerate and isotretinoin: corticosteroid decreases and isotretinoin increases the level of transforming growth factor-beta in suction blister fluid[J]. Skin Pharmacol Appl Skin Physiol, 2000;13:150-6
9 Song CZ, Tian X, Gelehrter TD. Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3[J]. Proc Natl Acad Sci USA, 1999; 96:11776-81
10 Parrelli JM, Meisler N, Cutroneo KR. Identification of a glucocorticoid response element in the human transforming growth factor beta 1 gene promoter[J]. Int J Biochem Cell Biol, 1998; 30: 623-7

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[3]	YANG Zhian, ZHAO Yan, HE Yao, LIU Weiying, YU Qin. Pyroptosis mediated renal injury caused by chronic intermittent hypoxia and the intervention effect of edaravone in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 10-18.
[4]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[5]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[6]	WANG Zhen, QUAN Haiyan, HONG Chenliang, YUAN Lijialong, QIN Xuping. Swimming improves renal function of diabetic mice by promoting autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 632-638.
[7]	DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651.
[8]	ZHU Xinru, HUANG Xin. Roles of indoxyl sulfate in complications of chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 672-679.
[9]	YE Xiaodi, MIAO Yunping, CHEN Aiying, CHENG Min, TIAN Xuejun, ZHENG Gaoli . Optimization and verification of orthotopic non-muscle invasive bladder cancer model in nude mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 473-480.
[10]	ZHAN Zhuqin, BAI Haitao. Effects of different doses of dexamethasone on angiotensin II, its receptors and NO levels in septic kidney injury rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 995-1004.
[11]	LIU Yunfan, DU Yuemei, LIU Xiaoyi, GAO Liping. Effects of lycium barbarum polysaccharides on cis-dichlorodiamineplatinum (II)-induced apoptosis in mouse testis sertoli cells TM4#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 624-630.
[12]	WANG Xiangyi, SHENG Jie, WANG Xiu, GUO Yan, CHEN Zhiwu. Distribution of deuterosuccinylcholine chloride in rats determined by UPLC-MS/MS method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 271-277.
[13]	LIU Yadong, LU Xiaowei, LIU Zhigang. Effects of EPO on serum calcitonin gene-related peptide in patients with acute spinal cord injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 933-937.
[14]	JIANG Haoming，CHEN Xiang, LI Zhen, GU Chengping. Clinical efficacy of monosialotetrahexose ganglioside combined with mouse nerve growth factor in the treatment of neonatal hypoxic ischemic encephalopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 301-306.
[15]	LIN Hai, WANG Zijing, WANG Shibiao, GUO Xiaofeng, GUO Renming, WENG Bin. Clinical efficacy and the effect on Hypothalamic--Pituitary--Adrenal Axis of differentdoses of methylprednisolone in the treatment of children with septic shock indecompensation stage [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 77-82.

Inhibition effects of methylprednisolone on over-expression of transforming growth factor-β₁ (TGF-β₁) in kidneys of BXSB mice

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments